Valproate and the symptomatic treatment of schizophrenia spectrum patients

 

 Buy Article Permissions and Reprints

Valproate is currently one of the most frequently prescribed drugs in schizophrenia spectrum disorders. However, surprisingly little is known from controlled studies. Also, no review articles are available. Here, we summarize basic and clinical research on valproate and its application for treatment in schizophrenia spectrum disorders. The molecular and physiological effects of valproate are outlined. It is discussed how the effects of valproate on the cellular level involving serotonin, GABA, glutamate, sodium-channels, membrane fluidity and RNA-expression may account for its clinical effect in schizophrenia spectrum patients. The target symptoms are a reduction of psychomotor agitation and aggression, possibly reflecting a drug effect on temporal lobe pathology, which is considered to be involved in the etiology of schizophrenic illness.

References

• 1 Adler L E, Olincy A, Waldo M, Harris J G, Griffith J, Stevens K, Flach K, Nagamoto K, Blickford P, Leonard S, Freedman R. Schizophrenia, sensory gating, and nicotinic receptors.  Schiz Bull. 1998;  24 189-202
  PubMedGoogle Scholar
• 2 Albus H, Williamson R. Electrophysiologic analysis of the actions of valproate on pyramidal neurons in the rat hippocampal slice.  Epilepsia. 1998;  39 124-139
  PubMedGoogle Scholar
• 3 Angst J, Stassen H H, Gross G, Huber G, Stone M H. Suicide in affective and shcizoaffective disorders. In: Maneros A, Tsuang MT (eds) Affective and schizoaffective disorders. Berlin; Springer 1990: 168-186
  Google Scholar
• 4 Altamura A C, Basile R, Mauri M, Cazzullo C L. Le valpromide (Depamide) dans le traitement d'etats psychotiques aigus.  Acta Psychiat Belg. 1986;  86 297-304
  PubMedGoogle Scholar
• 5 Amen D G, Stubblefield M, Carmicheal B, Thisted R. Brain SPECT findings and aggressiveness.  Ann Clin Psychiatry. 1996;  8 129-137
  PubMedGoogle Scholar
• 6 Andreasen N C, Flaum M, Arndt S, Alliger R, Swayze V W. Positive and negative symptoms: assessment and validity. In: Morneros A, Andreasen NC, Tsuang M (eds) Negative versus positive schizophrenia. Berlin; Springer 1991: 28-51
  Google Scholar
• 7 Asghari V, Wang J F, Reiach J S, Young L T. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells.  Brain Res Mol Brain Res. 1998;  58 95-102
  PubMedGoogle Scholar
• 8 Baetz M, Bowen R C. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy.  Can J Psychiat. 1998;  43 73-77
  PubMedGoogle Scholar
• 9 Benes F M. Evidence for altered trisynaptic circuitry in schizophrenic hippocampus.  Biol Psychiatry. 1999;  46 589-599
  CrossrefPubMedGoogle Scholar
• 10 Bertolino A, Callicott J H, Elman I, Mattay V S, Tedeschi G, Frank A J, Breier A, Weinberger D R. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study.  Biol Psychiat. 1998;  43 641-648
  PubMedGoogle Scholar
• 11 Biggs C S, Pearce B R, Fowler L J, Whitton P S. The effect of sodium valproate on extracellular GABA and other aminoacids in the rat ventral hippocampus: an in vivo microdialysis study.  Brain Res. 1992;  594 138-142
  CrossrefPubMedGoogle Scholar
• 12 Bolanos J P, Medina J M. Effect of valproate on the metabolism of the central nervous system.  Life Sciences. 1997;  60 1933-1942
  CrossrefPubMedGoogle Scholar
• 13 Brockington I F, Perris C, Kendell R E, Hillier V E, Wainwright S. The course and outcome of cycloid psychosis.  Psychol Medicine. 1982;  12 97-105
  PubMedGoogle Scholar
• 14 Buchhalter J R, Dichter M A. Effects of valproic acid in cultured mammalian neurons.  Neurology. 1986;  36 259-262
  PubMedGoogle Scholar
• 15 Buda M, Tsuang M T, Fleming J A. Causes of death in DSM-III schizophrenics and other psychotics (atypical group): a comparison with the general population.  Arch Gen Psychiatry. 1998;  45 283-285
  PubMedGoogle Scholar
• 16 Burns A, Jacoby R, Levy R. Psychiatric phenomenon in Alzheimer's disease. IV: Disorders of behaviour.  Br J Psychiat. 1990;  157 86-94
  PubMedGoogle Scholar
• 17 Callicott J H, Egan M F, Bertolino A, Mattay V S, Langheim F JP, Duyn J H, Frank J A, Weinberger D R. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype.  Biol Psychiatry. 1988;  44 941-950
  PubMedGoogle Scholar
• 18 Chong S A, Tan C H, Lee E L, Liow P H. Augmentation of resperidone with valproic acid.  J Clin Psychiat. 1998;  59 430
  PubMedGoogle Scholar
• 19 Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health.  Psychiatry Quarterly. 1998;  69 283-300
  CrossrefPubMedGoogle Scholar
• 20 Clemente C D, Chase M H. Neurological substrates of aggressive behavior.  Ann Rev Physiol. 1973;  35 329-356
  PubMedGoogle Scholar
• 21 Cutting J C, Clarke A W, Mann A H. Cycloid psychosis: an investigation of the diagnostic concept.  Psychol Medicine. 1978;  8 637-648
  PubMedGoogle Scholar
• 22 Davis R, Peters D H, McTavish D. Valproic acid - a reappraisal of its pharmacological properties and clinical efficacy in epilepsy.  Drugs. 1994;  47 332-372
  PubMedGoogle Scholar
• 23 Dailey J W, Reith M E, Yan Q S, Li M Y, Jobe P C. Carbamazepine increases extracellular serotonin concentration: lack of antagonism by terodotoxin or zero Ca2+.  Eur J Pharmacol. 1997;  328 153-162
  CrossrefPubMedGoogle Scholar
• 24 Dailey J W, Reith M E, Steidley K R, Milbrandt J C, Jobe P C. Carbamazepine-induced release of serotonin from rat hippocampus in vitro.  Epilepsia. 1998;  39 1054-1063
  PubMedGoogle Scholar
• 25 Delgado J M. Aggression and defense under cerebral ratio control. In: Clemente CD, Lindsley DB (eds) Aggression and defense. . Los Angeles; Univ of California Press 1967
  Google Scholar
• 26 Deltito J A, Levitan J, Damore J, Hajal F, Zambenedetti M. Naturalistic experience with the use of divalproex sodium on an in-patient unit for adolescence psychiatric patients.  Acta Psychiat Scand. 1998;  97 236-240
  PubMedGoogle Scholar
• 27 Diener H C, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine.  Drugs. 1998;  56 811-824
  PubMedGoogle Scholar
• 28 Dixon J F, Hokin L E. The antibipolar drug valporate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and biphosphates.  Proc Natl Acad Sci USA. 1997;  94 4757-4760
  CrossrefPubMedGoogle Scholar
• 29 Donovan S J, Susser E S, Nunes E V, Stewart J W, Quitkin F M, Klein D F. Divalproex treatment of disrupture adolescents: a report of 10 cases.  J Clin Psychiatry. 1997;  56 12-15
  PubMedGoogle Scholar
• 30 Dose M, Hellweg R, Yassouridis A, Theison M, Emrich H M. Combined treatment of schizophrenic psychoses with haloperidol and valproate.  Pharmacopsychiatry. 1998;  31 122-125
  Article in Thieme ConnectPubMedGoogle Scholar
• 31 Emrich H M, Dose M, Von Zerssen D. The use of sodium valproate, carabamazepine, and oxcarbazepine in patients with affective disorders.  J Affect Disord. 1985;  8 243-250
  CrossrefPubMedGoogle Scholar
• 32 Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition.  Biol Psychiat. 1994;  36 487-488
  PubMedGoogle Scholar
• 33 Fisk G G, York S M. The effect of sodium valproate on tardive dyskinesia - revisited.  Br J Psychiatry. 1987;  150 542-546
  CrossrefPubMedGoogle Scholar
• 34 Ganong W F. Nervous system. Los Altos; Lange 1977
• 35 Gastaut H. Les troubles du comportement chez les epileptiques psychomoteurs.  Rev Neurol. 1955;  92 55-62
  PubMedGoogle Scholar
• 36 Gean P-W, Huang C-C, Hung C-R, Tsai J-J. Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices.  Brain Res Bull. 1994;  33 333-336
  CrossrefPubMedGoogle Scholar
• 37 Godin Y, Heiner L, Mark J, Mandel P. Effects of DI-n-proylacetate, and anticonvulsive compound, on GABA metabolism.  N Neurochem. 1969;  16 869-873
  PubMedGoogle Scholar
• 38 Grossmann F. A review of anticonvulsants in treating agitated demented elderly patients.  Pharmacotherapy. 1998;  18 600-606
  PubMedGoogle Scholar
• 39 Haas S, Vincent K, Holy J, Lippmann S. Divalproex: a possible treatment alternative for demented, elderly aggressive patients.  Annals Clin Psychiatry. 1997;  9 145-147
  PubMedGoogle Scholar
• 40 Hardman J G, Limbird L E, Molinoff P B, Ruddon R W, Goodman L S, Gilman A. The pharmacological basis of therapeutics. New York; McGraw-Hill 1996
• 41 Herrmann N. Valproic acid treatment of agitation in dementia.  Can J Psychiatry. 1998;  43 69-72
  PubMedGoogle Scholar
• 42 Hill D, Mitchell W. Epileptic anamnesis.  Fol Psychiat Neerl. 1952;  56 718-725
  PubMedGoogle Scholar
• 43 Hilty D M, Rodriguez G D, Hales R E. Intravenous valproate for rapid stabilization of agitationin neuropsychiatric disorders.  J Neuropsychiat Clin Neurosci. 1998;  10 356-366
  PubMedGoogle Scholar
• 44 Hitzemann R J, Harris R A, Loh H H. Pharmacological, developmental, and physiological regulation of synaptic membrane phospholipids.Phospholipids and cellular regulation, vol. I. In: Shinitzky M (ed) Phospholipids and cellular regulation, vol. I.  Boca Raton, FL 1985: 97-130
  Google Scholar
• 45 Hyde T, Casanova M, Kleinman J E, Weinberger D R. Neuroanatomical and neurochemical pathology in schizophrenia.  Am Psychiat Press Rev Psychiatry. 1991;  10 7-23
  PubMedGoogle Scholar
• 46 Hyman S E, Nestler E J. Initiation and adaptation: a paradigm for understanding psychotropic drug action.  Am J Psychiat. 1996;  153 151-162
  PubMedGoogle Scholar
• 47 Kahn D, Stevenson E, Douglas C J. Effect of sodium valproate in three patients with organic brain syndrome.  Am J Psychiat. 1988;  145 1010-1011
  PubMedGoogle Scholar
• 48 Kastner T, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in mental retardation.  J Clin Psychopharmacol. 1993;  13 448-451
  PubMedGoogle Scholar
• 49 Kausen J, Zimmermann P, Funfgeld E W, Klenke D, Henkel H. Effects of a GABA-mimetic drug (sodium valproate) on visually evoked potentials in chronic schizophrenics.  Neuropsychobiology. 1984;  11 59-64
  PubMedGoogle Scholar
• 50 Kavoussi R, Armstead P, Coccaro E. The neurobiology of impulse aggression. In: Fava M (ed) Anger, Aggresion, and Violence. The Psychiatric Clinics of North America 1997 20: 395-403
  Google Scholar
• 51 Kavoussi R J, Coccaro E F. Divalproex sodium for impulse aggressive behavior in patients with personality disorder.  J Clin Psychiat. 1998;  59 676-680
  CrossrefPubMedGoogle Scholar
• 52 Keck P E, McElroy S L, Friedman L M. Valproate and carbamazepine in the treatment of panic and post-traumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes.  J Clin Psychopharmacology. 1992;  12 36S-41S
  PubMedGoogle Scholar
• 53 Keck P E, McElroy S L, Strakowski S M. New developments in the pharmacologic treatment of schizoaffective disorder.  J Clin Psychiat. 1996;  57 41-48
  PubMedGoogle Scholar
• 54 Kennedy D, Koren G. Valproic acid use in psychiatry: issues in treating women of reproductive age.  J Psychiatry Neurosci. 1998;  23 223-228
  PubMedGoogle Scholar
• 55 Keshavan M S, Pettegrew J W. Magnetic resonance spectroscopy in schizophrenia and psychotic disorders. In: Krishnan KRR (ed) Brain Imaging Psychiatry. New York; Marcell-Dekker Inc 1997: 381-400
  Google Scholar
• 56 Ko G N, Korpi E R, Freed W J, Zalcman S J, Bigelow L B. Effects of valporic acid on behavior and plasma amino acid concentration in chronic schizophrenic patients.  Biol Psychiatry. 1985;  20 209-215
  CrossrefPubMedGoogle Scholar
• 57 Leonhard K. Aufteilung der endogenen Psychosen. Berlin; Akademie-Verlag 1957
• 58 Lewin J, Sumners D. Successful treatment of episodic dyscontrol with carbamazepine.  Br J Psychiat. 1992;  161 261-262
  PubMedGoogle Scholar
• 59 Lewis S W. The secondary schizophrenias. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Oxford; Blackwell Science 1995: 324-340
  Google Scholar
• 60 Licht R W. Drug treatment of mania: a critical review.  Acta Psychiat Scand. 1998;  97 387-397
  PubMedGoogle Scholar
• 61 Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia.  Br J Psychiatry. 1976;  129 140-119
  PubMedGoogle Scholar
• 62 Lipska B K, Jaskiw G E, Weinberger D R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia.  Neuropsychopharmacol. 1993;  9 67-75
  PubMedGoogle Scholar
• 63 Löscher W. Effect of inhibitors of GABA aminotransferase on the metabolism of gGABA in brain tissue and synaptosomal fractions.  J Neurochem Res. 1981;  36 1521-1527
  PubMedGoogle Scholar
• 64 Löscher W. In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats.  Neurosci Lett. 1993;  160 177-180
  CrossrefPubMedGoogle Scholar
• 65 Löscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain.  Neurochem Res. 1993;  18 485-202
  CrossrefPubMedGoogle Scholar
• 66 Longo L P, Salzman C. Valproic acid effects on serum concentration of clozapine and norclozapine.  Am J Psychiatry. 1995;  152 650
  PubMedGoogle Scholar
• 67 Lott A D, McElroy S L, Keys M A. Valproate in the treatment of behavioral agitation in elderly patients with dementia.  J Neuropsychiatry. 1995;  7 314-319
  PubMedGoogle Scholar
• 68 Luder A S, Parks J K, Frerman F, Parker W D. Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions.  J Clin Invest. 1990;  86 1574-1581
  PubMedGoogle Scholar
• 69 Meyer M C, Baldessarini R J, Goff D C, Centorrino F. Clinically significant interactions of psychotropic agents with antipsychotic drugs.  Drug Safety. 1996;  15 333-346
  PubMedGoogle Scholar
• 70 McElroy S L, Keck P E, Pope H G. Sodium valproate: its use in primary psychiatric disorders.  J Clin Psychopharmacology. 1987;  7 16-24
  PubMedGoogle Scholar
• 71 McElroy S L, Keck P E, Pope H G, Hudson J I. Valproate in primary psychiatric disorders: Literature review and clinical experience in a private psychiatric hospital. In: McElroy SL, Pope HG (eds) Use of anticonvulsants in psychiatry: recent advances. Oxford; Healt Care Inc, Clifton 1988: 25-42
  Google Scholar
• 72 McElroy S L, Keck P E, Pope H G, Hudson J I. Valproate in psychiatric disorders: literature review and clinical guidelines.  J Clin Psychiatry. 1989;  50 ((Suppl. 3)) 23-29
  PubMedGoogle Scholar
• 73 Meltzer H Y. Treatment of the neuroleptic-nonreponsive schizophrenic patient.  Schiz Bull. 1992;  18 515-542
  PubMedGoogle Scholar
• 74 Morinigo A, Martin J, Gonzalez S, Mateo I. Treatment of resistant schizophrenia with valporate and neuroleptic drugs.  Hillside J Clin Psychiat. 1989;  11 199-207
  PubMedGoogle Scholar
• 75 Olney J W, Farber N B. Glutamate receptor dysfunction and schizophrenia.  Arch Gen Psychiat. 1995;  52 998-1007
  PubMedGoogle Scholar
• 76 Paredes R G, Karam P, Highland L, Agmo A. GABAergic drugs and socio-sexual behavior.  Pharmacol Biochem Behavior. 1997;  58 291-298
  PubMedGoogle Scholar
• 77 Perreault P, Tancredi V, Avoli M. Failure of the antiepileptic drug valproic acid to modify synaptic and non-synaptic responses of CA1 hippocampal pyramidal cells maintained “in vitro”.  Epilepsy Res. 1989;  3 227-231
  CrossrefPubMedGoogle Scholar
• 78 Phillips I, Martin K F, Thompson K S, Heal D J. Weak blockade of AMPA receptor-mediated depolarisations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine.  Eur J Pharmacol. 1997;  337 189-195
  CrossrefPubMedGoogle Scholar
• 79 Preisendörfer U, Zeise M L, Klee M R. Valproate enhances inhibitory postsynaptic potentials in hippocampal neurons in vitro.  Brain Res. 1987;  435 213-219
  CrossrefPubMedGoogle Scholar
• 80 Prevey M L, Delaney R C, Cramer J A, Cattanach L, Collins J F, Mattson R H. Effect of valproate on cognitive functioning.  Arch Neurology. 1996;  53 1008-1016
  PubMedGoogle Scholar
• 81 Rauch S L, Hitzemann R J. Developmental changes in synaptic membrane order: A comparison of regions in the rat brain.  Dev Brain Res. 1986;  26 221-227
  CrossrefPubMedGoogle Scholar
• 82 Reuttens S, Castle D. Valproate and neuroleptic medication.  Br J Psychiatry. 1997;  170 484-485
  PubMedGoogle Scholar
• 83 Roy-Byrne P P, Ward N G, Donnelly P J. Valproate in anxiety and withdrawal syndromes.  J Clin Psychiat. 1989;  50 ((Suppl. 3)) 44-48
  PubMedGoogle Scholar
• 84 Sachdev P, Smith J S, Matheson J, Last P, Blumbergs P. Amygdalo-hippocamectomy for pathological aggression.  Aust. N Z J Psychiatry. 1992;  26 671-676
  PubMedGoogle Scholar
• 85 Sawaya M CB, Horton R W, Meldrun B S. Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA.  Epilepsia. 1975;  16 649-655
  PubMedGoogle Scholar
• 86 Seger D L. Antiepileptic drug actions. In: Haddad LM, Shannon MW (eds) Clinical management of poisoning and drug overdose. Winchester; Saunders 1998
  Google Scholar
• 87 Shinitsky M. Phospholipids and cellular regulation. Boca Raton; Fl: CRC 1985
• 88 Silverman R B, Andruszkiezwicz R, Nanavati S M, Taylor C P, Vartanian M G. 3-alkyl-4-aminobutyric acids; the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase.  J Med Chem. 1991;  34 2295-2298
  CrossrefPubMedGoogle Scholar
• 89 Stein D J, Simeon D, Frenkel M, Islam M N, Hollander E. An open trial of valproate in borderline personality disorder.  J Clin Psychiatry. 1995;  56 506-510
  PubMedGoogle Scholar
• 90 Taylor P J. Schizophrenia and the risk of violence. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Oxford; Blackwell Science 1995: 163-183
  Google Scholar
• 91 Tsuang M T, Levitt J J, Simpson J C. Schizoaffective disorder. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Oxford; Blackwell Science 1995: 46-57
  Google Scholar
• 92 Tulloch I F, Walter D S, Howe G M, Howe S J. The relationship between plasma concentration of valproic acid and its anticonvulsant and behavioral effects in rat.  Neuropharmacology. 1982;  21 555-562
  CrossrefPubMedGoogle Scholar
• 93 Van Blitterswijk W J, Van Hoeven R P, Van der Meer B W. Lipid structural order parameter (reciprocal of fluidity) in biomembranes derived from steady-state fluorescence polarization measurements.  Biochem Biophys Acta. 1981;  644 323-332
  PubMedGoogle Scholar
• 94 Van der Laan J W, De Boer T H, Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase.  J Neurochem. 1979;  32 1769-1780
  PubMedGoogle Scholar
• 95 Volkow N D, Tancredi L R, Grant C, Gillespie H. Brain glucose metabolism in violent psychiatric patients: a preliminary study.  Psychiat Res. 1995;  61 243-253
  PubMedGoogle Scholar
• 96 Vorhees C V, Rauch S, Hitzemann R J. Effects of short-term prenatal alcohol exposure on neuronal membrane order in rats.  Dev Brain Res. 1988;  38 161-166
  CrossrefPubMedGoogle Scholar
• 97 Vorhees C V, Rauch S L, Hitzemann R J. Prenatal phenytoin exposure decreases neuronal membrane order in rat offspring hippocampus.  Int J Dev Neuroscience. 1990;  8 283-288
  PubMedGoogle Scholar
• 98 Vorhees C V. Fetal anticonvulsant syndrome in rats: Dose- and period-response relationships of prenatal diphenylhydantoin, trimehadione, and phenobarbital exposure on the structural and functional development of the offspring.  J Pharmacol Exp Ther. 1983;  227 274-287
  PubMedGoogle Scholar
• 99 Vorhees C V. Fetal anticonvulsant syndrome in rats: effects on postnatal behavior and brain amino acid content.  Neurobehav Toxicol Teratol. 1985;  227 274-287
  PubMedGoogle Scholar
• 100 Vorhees C V. Behavioral teratogenicity of valproic acid: selective effects on behavior after prenatal exposure to rats.  Psychopharmacol. 1987;  92 173-179
  PubMedGoogle Scholar
• 101 Vorhees C V, Rauch S L, Hitzemann R J. Prenatal valproic acid exposure decreases neuronal membrane order in rat offspring hippocampus and cortex.  Neurotox Teratology. 1991;  13 471-474
  PubMedGoogle Scholar
• 102 Vriend J P, Alexiuk N AM. Effects of valproate on amino acid and monoamine concentrations in triatum of audiogenic seizure-prone Balb/c mice.  Mol Chem Neuropatol. 1996;  27 307-324
  PubMedGoogle Scholar
• 103 Wang J-F, Brown C, Young L T. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78.  Mol Pharmacol. 1999;  55 521-527
  PubMedGoogle Scholar
• 104 Weinberger D R. Implications of normal brain development for the pathogenesis of schizophrenia.  Arch Gen Psychiatry. 1987;  44 660-669
  PubMedGoogle Scholar
• 105 Weinberger D R. Cell Biology of the hippocampal formation in schizophrenia.  Biol Psychiatry. 1999;  45 395-402
  CrossrefPubMedGoogle Scholar
• 106 Whitton P S, Oreskovic D, Jernej B, Bulat M. Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain.  J Pharm Pharmacol. 1985;  37 199-200
  PubMedGoogle Scholar
• 107 Wilcox J A. Divalproex sodium as a treatment for borderline personality disorder.  Ann Clin Psych. 1995;  7 33-37
  PubMedGoogle Scholar
• 108 Winterer G, Ziller M, Dorn H, Frick K, Mulert C, Wuebben Y, Herrmann W M, Coppola R. Schizophrenia: Reduced Signal-to-Noise Ratio and Impaired Phase-Locking during Information Processing.  Clin Neurophysiol. 2000a;  3 837-849
  PubMedGoogle Scholar
• 109 Winterer G, Egan M F, Rädler T, Coppola C, Weinberger D R. An association between reduced interhemispheric EEG coherence in the temporal lobe and genetic risk for schizophrenia.  Schizophr Res (in press)
  Google Scholar
• 110 Wolkowitz O M. Rational polypharmacy in schizophrenia.  Ann Clin Psychiatry. 1993;  5 79-90
  PubMedGoogle Scholar
• 111 Wong M T, Lumsden J, Fenton G W. Electroencephalography, computed tomography and violence ratings of male patients in a maximum security mental hospital.  Acty Psychiat Scand. 1994;  90 97-101
  PubMedGoogle Scholar
• 112 Wroblewski B A, Joseph A B, Kupfer J, Kalliel K. Effectiveness of valproic acid on destructive and aggressive behaviors in patients with acquired brain injury.  Brain Injury. 1997;  11 37-47
  CrossrefPubMedGoogle Scholar
• 113 Yudofsky S, Silver J, Schneider S. Pharmacologic traetment of aggression.  Psychiatr Ann. 1987;  2 397-407
  PubMedGoogle Scholar
• 114 Zeise M L, Kasparow S, Zieglgänsberger W. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro.  Brain Res. 1991;  544 345-348
  CrossrefPubMedGoogle Scholar

G. Winterer

National Institutes of Health
National Institute of Mental Health
Clinical Brain Disorder Branch

10 Center Drive, Room 4s235 MSC 1379

Bethesda, MD, 20892-1379

USA

Phone: 001-301-594-0874

Email: wintereg@intra.nimh.nih.gov